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Key Points
• In older patients with AML
who are not suitable for
intensive treatment,
clofarabine doubles remission
rates
• Survival is not improved
compared with low-dose Ara-C
Better treatment is required for older patients with acute myeloid leukemia (AML) not
considered fit for intensive chemotherapy. We report a randomized comparison of low-
dose Ara-C (LDAC) vs the novel nucleoside, clofarabine, in untreated older patients
with AML and high-risk myelodysplastic syndrome (MDS). A total of 406 patients with
de novo (62%), secondary disease (24%), or high-risk MDS (>10% marrow blasts) (15%),
median age 74 years, were randomized to LDAC 20 mg twice daily for 10 days every 6
weeks or clofarabine 20 mg/m2 on days 1 to 5, both for up to 4 courses. These patients
had more adverse demographics than contemporaneous intensively treated patients.
The overall remission rate was 28%, and 2-year survival was 13%. Clofarabine signif-
icantly improved complete remission (22% vs 12%; hazard ratio [HR] 5 0.47 [0.28-0.79];
P 5 .005) and overall response (38% vs 19%; HR 5 0.41 [0.26-0.62]; P < .0001), but there was no difference in overall survival,
explained by poorer survival in the clofarabine patients who did not gain complete remission and also following relapse.
Clofarabine was more myelosuppressive and required more supportive care. Although clofarabine doubled remission rates, overall
survival was not improved overall or in any subgroup. The treatment of patients of the type treated here remains a major unmet
need. This trial was registered at www.clinicaltrials.gov as #ISRCTN 11036523. (Blood. 2013;122(8):1384-1394)
Introduction
An important proportion of older patients with acute myeloid
leukemia (AML) do not receive conventional chemotherapy with a
“317” or equivalent approach. Population studies indicate that this
may be as many as 60% to 70% of patients.1,2 Epidemiological
studies carried out in Sweden indicate that the survival was better
in the localities where older patients tended to receive an intensive
approach than in those locations where patients received a non-
intensive or palliative approach.3 Because the reasons why patients
were allocated to one or other treatment approach was not doc-
umented, this information does not provide complete evidence to
support one or another approach. In a small randomized study that
tested a policy of immediate vs delayed intensive therapy, there
was no difference in survival.4 In our UK LRF AML14 trial, we
attempted to address the issue of which patients should receive an
intensive or a nonintensive strategy, hoping to recruit sufﬁcient
patients to deﬁne subsets in which one or another approach could
be recommended. Out of a total recruitment of 1600 patients, only
8 were randomized.5 In a multivariate analysis, one of the most
signiﬁcant factors associated with the allocated treatment was the
treating doctor, which suggested that physician preference plays
an important role in this decision. In this trial, we established that
low-dose Ara-C (LDAC) was superior to supportive care with
no evidence of extra toxicity or supportive care required.6 The
schedule of Ara-C 20 mg twice daily for 10 days is not satisfactory
treatment, except for the 15% to 20% who enter remission where
the median survival is 15 months, but it remains to be beaten by
alternatives in a randomized comparison. Popular alternatives
include demethylation agents, but they have not been proven to be
superior to this schedule of LDAC, either because there was
insufﬁcient power to detect a difference in the 20% to 30% blast
population7 or because a single daily dose was used.8 Because there
is an urgent need to improve treatment in this patient population
and there are a number of potential novel agents or combinations
emerging, we developed a program in which we designated “Pick a
Winner,” which was aimed at rapidly identifying new treatments
for this patient population that were capable of making a clinically
Submitted April 12, 2013; accepted June 25, 2013. Prepublished online as
Blood First Edition paper, July 9, 2013; DOI 10.1182/blood-2013-04-496596.
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Table 1. Characteristics of patients randomized and comparison with contemporaneous intensive patients
Characteristic LDAC (n 5 206) Clofarabine (n 5 200) Intensive (n 5 1507) P value vs intensive
Age (y)
,60 3 3 24 ,.0001*
60-64 9 5 412 ,.0001†
65-69 30 26 595
70-74 65 68 373
75-79 60 73 96
$80 39 25 7
Median (range) 74 (54-90) 74 (51-87) 67 (51-84)
Sex
Female 86 75 586 .8
Male 120 125 921
Diagnosis
De novo 126 124 1083 .0003
Secondary 50 47 265
High-risk MDS 30 29 159
WBC (3 109/L)
,10 130 134 928 .04*
10-49.9 55 49 385 .15†
50-99.9 14 12 107
$100 7 5 87
Median 4.6 (0.5-175.0) 4.3 (0.5-260.6) 5.1 (0.2-454.0)
Performance status
WHO PS 0 75 72 900 ,.0001*
WHO PS 1 106 100 510
WHO PS 2 16 22 60
WHO PS 3,4 9 6 37
Cytogenetics
Favorable 2 2 41 .12*
Intermediate 85 93 840
Adverse 33 31 260
Unknown 86 74 366
Wheatley group
Good 7 5 390 ,.0001*
Standard 95 92 550
Poor 104 103 567
FLT3-ITD
Wild-type 85 101 472 .3
Mutant 20 9 93
Unknown 101 90 942
NPM1
Wild-type 85 95 390 .6
Mutant 27 17 106
Unknown 94 78 1021
Comorbidity
Arrhythmia 18/199 (9%) 26/194 (13%) 69/1456 (5%) ,.0001
Cardiac 49/202 (24%) 53/193 (27%) 174/1472 (12%) ,.0001
Cerebrovascular 8/202 (4%) 11/195 (6%) 58/1477 (4%) .4
Diabetes 26/204 (13%) 33/195 (17%) 121/1481 (8%) ,.0001
Mild hepatic 13/203 (6%) 10/195 (5%) 68/1478 (5%) .3
Severe hepatic 1/203 (,0.5%) 3/195 (2%) 21/1480 (1%) .5
Heart valve disease 5/203 (2%) 9/194 (5%) 15/1472 (1%) .0003
Inflammatory bowel 2/202 (1%) 2/199 (1%) 37/1475 (3%) .07
Infection 27/204 (13%) 30/194 (15%) 193/1467 (13%) .5
Obesity 14/204 (7%) 20/195 (10%) 95/1476 (6%) .15
Peptic ulcer 3/203 (1%) 5/195 (3%) 21/1479 (1%) .4
Prior tumor 22/204 (11%) 20/195 (10%) 100/1480 (7%) .01
Psychiatric 7/198 (4%) 6/195 (3%) 32/1474 (2%) .19
Severe pulmonary 3/201 (1%) 3/193 (2%) 15/1461 (1%) .4
Renal 0/203 3/194 (2%) 28/1480 (2%) .11
Rheumatologic 19/203 (9%) 18/195 (9%) 83/1477 (6%) .008
Other 92/193 (48%) 89/183 (49%) 425/1417 (30%) ,.0001
PS, performance status.
*Mantel Haenszel test for trend.
†Wilcoxon rank sum test; all other tests by x2 analysis.
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worthwhile improvement in outcome. This has been described in
detail elsewhere.9 We report here the Pick-a-Winner comparison of
clofarabine vs LDAC as part of the UK National Cancer Research
Institute AML16 trial (ISRCTN 11036523).
Clofarabine (2-chloro-29-ﬂuoro-deoxy-9-b-D-arabinofuranosyl-
adenine) was designed to incorporate the beneﬁcial properties of
ﬂudarabine and cladribine, which are active as single agents in AML
but at dose levels associated with prohibitive toxicity due to the
cleavage product 2-ﬂuoroadenine being converted to the toxic
2-ﬂuoroadenosine.10,11 Clofarabine is the result of a program of de-
velopment exploring a series of chemical modiﬁcations to minimize
cleavage while retaining activity.12 It depends on membrane nucle-
oside transporters for cell entry and is sequentially phosphorylated
in deoxycytidine-kinase–dependent steps to the triphosphate, the
active form of which is retained within cells for longer than other
purine nucleoside analogs. Following initial studies in relapsed
disease that conﬁrmed its activity,13 2 reports incorporating 3 unran-
domized studies14,15 assessed the front-line activity in older patients
using lower doses. These studies were consistent is delivering
complete remission (CR) to more than 40% of patients, and of
interest this responsiveness did not seem to be limited by age or
cytogenetic risk group. It also had the potential of being orally
available. Clofarabine was therefore identiﬁed as a candidate to
be included in the Pick-a-Winner program to be randomized
against LDAC.
Patients and methods
Patients with AML (de novo or secondary) and high-risk myelodysplastic
syndrome (MDS) (.10% marrow blasts) could enter the study. During the
study, all centers had within the protocol the option to receive an intensive
chemotherapy approach and the reasons why patients were not treated
intensively, and details of comorbidity (using the Sorror index16 components)
were collected at entry. Patients could be randomized between LDAC and
any of the concurrently available options for which they were eligible. To
enter the LDAC vs clofarabine randomization, patients had to have renal
function test results within the local upper limit of normal. Patients with
acute promyelocytic leukemia or blast transformation of chronic myeloid
leukemia were excluded. Diagnosis and response deﬁnitions were assessed
by the local investigator. Cytogenetic and immunophenotypic character-
ization was carried out in regional reference laboratories that participate in
national quality assurance schemes. Patients were required to give written
consent and the trial was approved by the Wales Research Ethics Committee
in compliance with the Declaration of Helsinki.
LDAC was given as a twice-daily 20-mg subcutaneous injection for
10 days with the aim of delivering 4 courses at approximately 6-week
intervals, and clofarabine was given as 20 mg/m2 daily for 5 days by in-
travenous infusion for 4 courses approximately 4 to 6 weeks apart. Patients
who were considered to be beneﬁting (CR or stable disease) were permitted
to receive additional courses of treatment.
Adverse events and toxicity were recorded as deﬁned by the National
Cancer Institute Common Terminology Criteria version 3.
Statistical considerations
Definitions of end points
The protocol deﬁned CR as a normocellular bone marrow aspirate
containing,5% leukemic blasts and showing evidence of normal
maturation of other marrow elements. Persistence of myelodysplastic
features did not preclude the diagnosis of CR. Although not in the
original protocol, in this report, to achieve CR, patients required
neutrophil recovery to 1.0 3 109/L and platelets to 100 3 109/L,
without evidence of extramedullary disease. Patients who achieved
CR according to the protocol, but without count recovery, are denoted
here as CRi. Assessment of remission status was undertaken after
each treatment course until remission status was conﬁrmed.
Following the international guidelines,17 overall survival (OS)
is deﬁned as the time from randomization to death. For remitters,
survival from CR is deﬁned as the time from CR/CRi (ﬁrst report)
until death. Relapse-free survival is the time from remission to
either death or relapse, whichever occurs ﬁrst. Surviving patients
are censored at date last seen, and follow-up is complete to January
1, 2012. Median follow-up for survival is 25 months (range, 1-53
months). Survival percentages are quoted at 2 years.
Statistical methods
All analyses are by intention to treat. Categorical end points (eg,
CR rates) were compared using Mantel-Haenszel tests, giving Peto
odds ratios and conﬁdence intervals. Continuous variables were
analyzed by parametric (Student t test) or nonparametric (Wilcoxon
Figure 1. CONSORT diagram.
Table 2. Reasons for choosing nonintensive therapy
Reason LDAC Clofarabine
Age 134/205 (65%) 136/196 (69%)
Fitness 130/205 (63%) 117/196 (60%)
Other 29/204 (14%) 18/196 (9%)
Patient choice (QoL) 16 9
Clinician decision 1 1
NI the only option at this center 2 3
Prior cancer 2 0
Heart disease 3 3
Hip replacement 1 0
COPD 1 0
Secondary disease 1 0
Psychiatric 0 1
Other 3 1
COPD, chronic obstructive pulmonary disease; NI, nonintensive; QoL, quality of life.
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rank sum) tests as appropriate. Time-to-event outcomes were analyzed
using the log-rank test with Kaplan-Meier survival curves. Odds
ratios (ORs) and hazard ratios (HRs) ,1 indicate beneﬁt for
clofarabine over LDAC. Effect sizes are given with 95% conﬁdence
intervals throughout.
In addition to overall analyses, subgroup analyses were performed
by the randomization stratiﬁcation parameters and other impor-
tant variables, with suitable tests for interaction. Because of the
well-known dangers of subgroup analysis, these were interpreted
cautiously.
Under the rules of the Pick-a-Winner design, the Data Moni-
toring and Ethics Committee (DMEC) would conﬁdentially examine
data once CR information was complete for 100 patients. In order
to proceed, there needed to be a 2.5% improvement or greater in
overall remission rate (CR 1 CRi). This occurred in September
2008, when the remission rates were respectively 34% (clofarabine)
vs 15% (LDAC). The trial then continued until 200 patients were
accrued, at which point there needed to be at least a 7.5% im-
provement in overall remission rate. At this assessment, in March
2010, the remission rates were 41% versus 21%. The DMEC therefore
recommended completion of the trial with 200 patients in each arm,
sufﬁcient to give 80% power to detect a doubling of 2-year survival,
from 11% (as seen in our AML14 trial) to 22% at P , .01.
Results
Between August 2006 and April 2011, 406 patients entered the
randomization from 109 centers in the UK, Denmark, and Australia,
with a median age of 74 years (range, 51-90 years) (Table 1).
Figure 1 shows a CONSORT diagram of the disposition of the
patients. Sixty-two percent had de novo disease, 24% secondary
AML, and 15% high-risk MDS (.10% blasts); 2% had favorable
cytogenetics, 72% intermediate, and 26% adverse. By Wheatley
score,18 3% were good, 46% standard, and 51% poor risk; 13% had a
WHO performance score >2. The characteristic of the randomized
patients and contemporaneous patients given intensive chemotherapy
in participating centers is shown in Table 1, which conﬁrms that
the patients in this study were signiﬁcantly different from those
entering the intensive treatment approach, even though cytoge-
netic data were not available to the investigator at entry.
The reasons for choosing a nonintensive treatment approach
and the comorbidities recorded at entry are listed in Table 2. Age
and a general assessment of “ﬁtness” accounted for two-thirds of
the reasons given. The comorbidities were signiﬁcantly different in
the randomized patients compared with those treated intensively
but were balanced between the study arms. The main differences were
cardiac, diabetes, rheumatologic, prior tumors, and inﬂammatory
bowel disease (Table 1).
Overall, 95% of patients received at least 1 course of treatment
(LDAC 96%, clofarabine 94%), with 94% receiving their allocated
treatment in course 1 (LDAC 95%, clofarabine 93%). The median
number of courses for each group was 2 for both LDAC (mean,
3.0; range, 0-8) and clofarabine (mean, 2.1; range, 0-8); patients
allocated to LDAC received more courses of treatment on average
than clofarabine (P , .0001). Treatment continuation beyond 4
courses was given to 23 of 106 remitters (22%) and 23 of 114 patients
(20%) with stable disease. Of patients allocated to clofarabine, 2, 1,
1, and 2 received 5, 6, 7, or 8 courses, while 7, 13, 4, and 16 LDAC
patients received 5, 6, 7, and 8 courses, respectively. Only 1 patient
allocated to clofarabine received more than 4 courses of clofarabine,
the others receiving LDAC beyond course 4.
Remission induction
The overall response rate was signiﬁcantly improved in the
clofarabine arm (38% vs 19%; OR5 0.41 [0.26-0.62]; P, .0001),
which included a superior rate of CR (22% vs 12%; OR 5 0.47
[0.28-0.79]; P 5 .005) and CRi (16% vs 8%). The beneﬁt was
due to less disease resistance (44% vs 67%; OR 5 0.39 [0.27-0.58];
P , .0001; Table 3). Of the remissions achieved in the clofarabine
arm with data, 45% (17% of all patients with remission data) were
recorded after 1 course and 55% (21% of patients) after 2 or more
courses, whereas in the LDAC arm 23% of remissions (4% of
patients) were recorded after course 1 and 73% of remissions
(15% of patients) required 2 or more courses (P 5 .0005 for
number of courses among remitters). The median time to CR was
113 days (LDAC) and 68 days (clofarabine), respectively.
Table 3. Outcomes for patients by randomized allocation
LDAC Clo HR/OR (95% CI) P value
CR 12% 22% 0.47 (0.28-0.79) .005
CRi 8% 16%
ORR (CR 1 CRi) 19% 38% 0.41 (0.26-0.62) ,.0001
Resistant disease 67% 44% 0.39 (0.27-0.58) ,.0001
Induction death 13% 18% 1.42 (0.83-2.44) .2
30-d mortality 13% 18%
60-d mortality 26% 32%
2-y survival 12% 13% 0.96 (0.78-1.19) .7
2-y RFS 8% 20% 0.76 (0.49-1.19) .2
2-y survival from CR 44% 26% 1.19 (0.74-1.91) .5
2-y survival from relapse 8% 0% 1.91 (1.10-3.31) .02
2-y survival for non-CR 4% 3% 1.37 (1.06-1.76) .02
CI, confidence interval; Clo, clofarabine; ORR, overall remission rate; RFS,
relapse-free survival.
Table 4. Toxicity and resource usage by randomization arm
Toxicity
LDAC Clofarabine
P value
% grade 3-4
(mean grade)
% grade 3-4
(mean grade)
Course 1
Nausea 4% (0.5) 9% (0.9) ,.0001
Oral 5% (0.5) 7% (0.8) 1.0
Diarrhea 0% (0.4) 4% (0.4) ,.0001
Cardiac 6% (0.3) 8% (0.5) .005
Liver AST 3% (0.3) 7% (0.6) .16
Liver ALT 3% (0.4) 9% (1.0) ,.0001
Bilirubin 3% (0.5) 7% (1.1) ,.0001
Mean blood units 5.9 8.9 ,.0001
Mean platelet units 3.6 7.2 ,.0001
Mean days on antibiotics 7.1 11.6 ,.0001
Mean nights in hospital 13.4 20.3 ,.0001
Course 2
Nausea 0% (0.4) 2% (0.7) .0004
Oral 2% (0.2) 6% (0.5) .02
Diarrhea 1% (0.4) 1% (0.2) .02
Cardiac 1% (0.1) 2% (0.2) .4
Liver AST 0% (0.2) 12% (0.9) .0002
Liver ALT 1% (0.3) 9% (0.9) ,.0001
Bilirubin 1% (0.3) 1% (0.6) .0001
Mean blood units 5.4 6.0 .12
Mean platelet units 2.7 4.1 .004
Mean days on antibiotics 3.7 6.6 .002
Mean nights in hospital 9.2 12.3 .003
ALT, alanine transaminase; AST, aspartate transaminase.
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Toxicity and resource use
Grade 3 or 4 gastrointestinal and hepatic toxicity was signiﬁcantly
greater in patients given clofarabine (Table 4), but this was generally
manageable. The supportive care requirements, days in hospital, and
days on antibiotics were signiﬁcantly greater in the clofarabine arm,
reﬂecting the increased level of myelosuppression (Table 4).
Postinduction outcomes
Remission failures. A total of 166 of the 206 patients (81%) in the
LDACarm and 123 of the 198 patients (62%) in the clofarabine armwith
remissionstatus failed toenterCR.Among thesepatients, thesurvivalwas
worse in the clofarabine arm (median survival was 107 days for LDAC
vs 60 days for clofarabine; HR5 1.37 [1.06-1.76]; P5 .02; Figure 2A).
Figure 2. Outcomes by randomization arm. (A) Survival for patients not achieving remission. (B) Relapse-free survival. (C) Survival from relapse. (D) OS.
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Duration of remission. The median duration of remission/
relapse-free survival in the 40 LDAC patients was not signiﬁcantly
different from the 75 clofarabine remitters (8% vs 20% at 2 years;
HR 5 0.76 [0.49-1.19]; P 5 .5; Figure 2B).
Survival from relapse. The survival of the of the 31 LDAC
patients who relapsed (median survival from relapse, 40 weeks)
was signiﬁcantly better than for the 41 clofarabine patients who
relapsed (median survival, 20 weeks; HR 5 1.91 [1.10-3.31];
P 5 .02; Figure 2C). Of the 41 patients on clofarabine who
relapsed, 7 of 39 are known to have received further treatment,
which was daunorubicin/Ara-C (n 5 1) or cytarabine alone (n 5 6).
A higher proportion of LDAC patients (16 of 30; P 5 .002) who
Figure 2. (Continued).
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relapsed received further therapy, which was daunorubicin/Ara-C
(n 5 1), ﬂudarabine/Ara-C/G-CSF (n 5 1), Ara-C (n 5 11),
hydroxyurea (n 5 1), etoposide (n 5 1), or azacitidine (n 5 1).
Overall survival. Because the survival of LDAC patients who
failed to enter CR or who relapsed from CR was superior to that
of clofarabine patients and the duration of remission was not
Figure 3. Stratified analyses of remission and OS. (A) Overall remission rate. (B) OS.
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significantly inferior to clofarabine, the net result was that there
was no OS difference between the arms (12% vs 13% at 2 years;
HR 5 0.96 [0.78-1.19]; P 5 .7; Figure 2D).
Exploratory subgroup analysis of demographics, cytogenetics,
and molecular characteristics indicated that the beneﬁcial effect on
remission achievement could be seen in all subgroups (Figure 3A),
Figure 3. (Continued).
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but there was no subgroup in which a survival beneﬁt could be
found (Figure 3B).
Discussion
The older patient with AML presents a therapeutic dilemma. Although
many studies have delivered conventional induction chemotherapy,
which has successfully delivered a remission, most patients will
relapse within a few months. This has led to a trend of loss of
conﬁdence in this approach, even in some cases for patients who
are judged as likely to withstand intensive therapy. There are many
patients who either do not wish to accept intensive treatment or
who are advised that it represents an undue risk with little durable
beneﬁt. There are no universally agreed objective criteria to help
with this decision. It was hoped that by randomizing this question
in our AML14 trial, we would be able to identify such criteria. While
age alone serves as a useful surrogate for predicting outcome, it is
not, of itself, necessarily the correct parameter. However, there are
many patients who are not treated with standard chemotherapy and
in the past have been managed by best supportive care. A randomized
comparison established that LDAC was superior to best supportive
care without adding toxicity, thus suggesting LDAC as a standard
of care, albeit far from ideal. Some patients beneﬁt from therapy
with demethylation agents, but they have not yet been shown in
randomized studies to be superior to LDAC as delivered in the
AML14 trial. New treatments are urgently required.
Clofarabine was clinically developed by the MD Anderson in-
vestigators and proved to be effective as monotherapy for the
treatment of relapsed AML and ALL. Given its favorable toxicity
proﬁle, potential for oral administration, and similarity to ﬂudar-
abine, it became a potential candidate novel therapy for the older
patient. Three unrandomized phase 2 trials conﬁrmed this hope and
produced very similar results in that CR was seen in about 40% of
patients with similar efﬁcacy in patients under or over 70 years or
with an adverse karyotype. These trials did not establish the duration
of response. In one of these pilot trials, because of concerns about
renal toxicity a dose level of 20 mg/m2 was tested in a small number
of patients against the conventional 30-mg/m2 dose and produced
a similar efﬁcacy but with a more favorable toxicity proﬁle. For
this reason, the 20-mg/m2 dose was taken forward in this study.
There therefore remains the possibility that the 30-mg/m2 dose
could have been beneﬁcial.
The study here reported is the only randomized trial comparing
clofarabine monotherapy. According to the rules of Pick a Winner,
the DMEC, in a conﬁdential analysis, required at least a 2.5% im-
provement in remission rate in the ﬁrst 100 randomized patients.
This was achieved, and therefore the trial continued to recruit with
OS as the primary end point. In spite of doubling the remission
rate, the OS was not improved. There were a number of reasons for
this. Recipients of clofarabine who failed to achieve CR survived
less well than LDAC patients who did not enter CR. Survival in
patients who achieved CR but relapsed survived less well in the
clofarabine arm. It might be expected that a reason for not showing
a survival beneﬁt, having doubled the remission rate, was that
clofarabine was able to achieve remissions in more resistant
patients, which may result in a shorter duration of remission. This
was not the case, because the relapse-free survival was similar in
both arms. The increased remission rate was obtained at the “cost” of
more toxicity and supportive care. The phase 2 trials suggested that
the efﬁcacy of clofarabine was seen irrespective of adverse
cytogenetics or age, so it might have been expected that these
subgroups at least would show beneﬁt against LDAC. This was not
the case.
Clofarabine is clearly an effective drug. Our assumption in
judging a new agent is that if it delivers a better remission rate,
then it should improve survival. But the evidence seen here is
similar to that seen with the addition of gemtuzumab ozogamicin
to LDAC, which also doubled the remission rate but did not
improve survival.19 The experience with demethylation agents
raises the possibility that, in older patients, it may be possible
to improve survival without improving the rate of remission. It could,
with some justiﬁcation, be assumed that being in remission is pref-
erable even though survival is not extended. In this randomization,
quality-of-life information to support that assumption was not
collected but is now incorporated in the Pick-a-Winner design. So
the challenge is to maintain remission. While the 20-mg/m2 dose
was well tolerated in this trial, it was only possible to deliver an
average of 3 courses, even to those who entered remission, although
survival was better for patients who received more courses (P5 .0005
for trend over number of courses of treatment delivered). This
raises the possibility that if more courses could be delivered,
perhaps by lowering the dose, then it may be possible to prolong
remission. Perhaps a priority should be to deliver effective treatment
at a dose and periodicity that increase compliance.
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